CN117098538A - 治疗方法 - Google Patents

治疗方法 Download PDF

Info

Publication number
CN117098538A
CN117098538A CN202280025886.8A CN202280025886A CN117098538A CN 117098538 A CN117098538 A CN 117098538A CN 202280025886 A CN202280025886 A CN 202280025886A CN 117098538 A CN117098538 A CN 117098538A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
subject
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280025886.8A
Other languages
English (en)
Chinese (zh)
Inventor
B·S·科勒
C·M·吉布森
A·W·J·范特霍夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celeco Treatment Co ltd
Original Assignee
Celeco Treatment Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celeco Treatment Co ltd filed Critical Celeco Treatment Co ltd
Publication of CN117098538A publication Critical patent/CN117098538A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280025886.8A 2021-02-17 2022-02-16 治疗方法 Pending CN117098538A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163150301P 2021-02-17 2021-02-17
US63/150,301 2021-02-17
PCT/US2022/016571 WO2022177968A1 (en) 2021-02-17 2022-02-16 Therapeutic methods

Publications (1)

Publication Number Publication Date
CN117098538A true CN117098538A (zh) 2023-11-21

Family

ID=82931154

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280025886.8A Pending CN117098538A (zh) 2021-02-17 2022-02-16 治疗方法

Country Status (10)

Country Link
US (1) US20250268902A1 (https=)
EP (1) EP4294402A4 (https=)
JP (1) JP2024507294A (https=)
KR (1) KR20230157354A (https=)
CN (1) CN117098538A (https=)
AU (1) AU2022224562A1 (https=)
BR (1) BR112023016459A2 (https=)
CA (1) CA3211215A1 (https=)
MX (1) MX2023009620A (https=)
WO (1) WO2022177968A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026019771A1 (en) * 2024-07-15 2026-01-22 Celecor Therapeutics, Inc. Zalunfiban for use in the treatment of thrombotic disorder in patients with renal impairment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104936598A (zh) * 2012-01-16 2015-09-23 洛克菲勒大学 有机化合物
WO2019246085A1 (en) * 2018-06-19 2019-12-26 Celecor Therapeutics, Inc. Deuterated ruc-4

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104936598A (zh) * 2012-01-16 2015-09-23 洛克菲勒大学 有机化合物
WO2019246085A1 (en) * 2018-06-19 2019-12-26 Celecor Therapeutics, Inc. Deuterated ruc-4

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KEREIAKES等: "First Human Use of RUC-4: A Nonactivating Second-Generation Small-Molecule Platelet Glycoprotein IIb/IIIa (Integrin αIIbβ3) Inhibitor Designed for Subcutaneous Point-of-Care Treatment of ST-Segment–Elevation Myocardial Infarction", 《JOURNAL OF THE AMERICAN HEART ASSOCIATION》, vol. 9, 31 December 2020 (2020-12-31), pages 1 - 28 *
张志寿: "《冠状动脉心肌桥诊断治疗学》", vol. 2, 28 February 2020, pages: 307 *

Also Published As

Publication number Publication date
WO2022177968A1 (en) 2022-08-25
EP4294402A4 (en) 2025-01-15
MX2023009620A (es) 2023-11-01
WO2022177968A9 (en) 2022-10-20
EP4294402A1 (en) 2023-12-27
JP2024507294A (ja) 2024-02-16
CA3211215A1 (en) 2022-08-25
BR112023016459A2 (pt) 2023-10-10
KR20230157354A (ko) 2023-11-16
AU2022224562A1 (en) 2023-08-31
WO2022177968A8 (en) 2022-11-17
US20250268902A1 (en) 2025-08-28

Similar Documents

Publication Publication Date Title
PT1928438E (pt) Método para tratamento de dependências de drogas e comportamentos
US20200315993A1 (en) Combinations of adrenergic receptor agonists for the treatment of type 2 diabetes
RS58750B1 (sr) Kombinovane formulacije neosaksitoksina za produženu lokalnu anesteziju
US20250099466A1 (en) Milvexian for prevention and treatment of thromboembolic disorders
US12042472B2 (en) Sublingual epinephrine tablets
HUP0203585A2 (hu) Gyógyszerkombinációk
JP2024056908A (ja) デュラグルチドを使用する方法およびデュラグルチドを含有する組成物
JP2024028652A (ja) 造影剤誘発急性腎障害の予防および／または処置
CN117098538A (zh) 治疗方法
IL268930B2 (en) Citrulline for the treatment of sickle cell crisis
JP7797440B2 (ja) 治療方法及びその剤形
WO2005112908A1 (en) Method for improving cognitive function
JP6419074B2 (ja) ショックの治療に使用するためのアドレナリンと抗うつ剤との組み合わせ
CN102327599A (zh) 用于治疗骨髓增生异常综合征的组合物和方法
JP2019514978A (ja) イブジラストを使用したアルコール依存症並びにうつ病及び／又は不快な気分の治療
JP2024507294A5 (https=)
WO2025209479A1 (en) Methods of treatment of immune thrombocytopenia using sovleplenib
JP2018507216A (ja) 多発性骨髄腫に対するパノビノスタット投与量
JP2024502821A5 (https=)
JP2005504009A (ja) 心臓保護のためのアデノシンａ１／ａ２アゴニストの投与のタイミングおよび継続
Dawson An investigation into the pathophysiology of a new model of transient focal cerebral ischaemia in the rat
Aronson MG Franzosi and R. Latini
Wang et al. Drugs Commonly Used to Treat Refractory Status Epilepticus in Clinical Practice
CN102026638A (zh) 喹诺酮和肉碱的组合
KR20130020944A (ko) 골수이형성 증후군을 치료하기 위한 조성물 및 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination